




## Product Catalog

**Your partner for human molecular diagnostics**



**Genetic Disorder**



**Genetic Predisposition**



**Cancer**



**Pharmacogenetics**




**Microbiology**

# Sample Preparation Kits

| Area                             | Product Name                              | REF   | Reg. Status | Unit Size | Application                                                       |
|----------------------------------|-------------------------------------------|-------|-------------|-----------|-------------------------------------------------------------------|
| StripAssays®<br>RealFast™ Assays | GEN*TRACT™<br>Blood DNA Extraction System | 2-014 | CE/IVD      | 100 Rxn   | DNA extraction from fresh, frozen and dried blood                 |
| StripAssays®<br>RealFast™ Assays | Spin Micro DNA Extraction Kit             | 2-020 | RUO         | 20 Rxn    | DNA extraction and purification from whole blood and buccal swabs |
| RealFast™ Assays                 | D2PCR™ Buffer                             | 2-030 | CE/IVD      | 100 Rxn   | For direct-to-PCR applications                                    |

## Workflow of RealFast™ Assays



## RealFast™ Assays

### Single marker detection

| Category | Clinical Topic                       | Product Name                  | REF 100 / 32 Rxn | Reg. Status | Description                                                                                                                                                                                         |
|----------|--------------------------------------|-------------------------------|------------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          | Carbamazepine Hypersensitivity       | HLA-A3101 RealFast™ Assay     | 7-640 / 7-643    | CE/IVD      | Detects the human leukocyte antigen (HLA) <i>HLA-A*31:01</i> allele, which is strongly associated with carbamazepine hypersensitivity reactions in Europeans and Japanese                           |
|          | Carbamazepine Hypersensitivity       | HLA-B1502 RealFast™ Assay     | 7-630 / 7-633    | CE/IVD      | Detects the human leukocyte antigen (HLA) <i>HLA-B*15:02</i> allele, which is strongly associated with carbamazepine hypersensitivity reactions in Asian populations                                |
|          | Carbohydrate Intolerance             | LCT -13910C>T RealFast™ Assay | 7-150 / 7-153    | CE/IVD      | Detects the most common polymorphism in the <i>lactase (LCT)</i> gene causing lactase non-persistence                                                                                               |
|          | Cardiovascular Diseases (CVD)        | FGB -455G>A RealFast™ Assay   | 7-230 / 7-233    | CE/IVD      | Identifies homozygosity for the -455G>A <i>fibrinogen beta-chain (FGB)</i> allele which may increase susceptibility to atherothrombosis in at-risk patients                                         |
|          | CVD                                  | FV Leiden RealFast™ Assay     | 7-110 / 7-113    | CE/IVD      | Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the <i>Factor V (FV)</i> gene                                                           |
|          | CVD                                  | FXII 46C>T RealFast™ Assay    | 7-240 / 7-243    | CE/IVD      | Identifies patients with the unfavorable TT genotype for <i>Factor XII (FXII)</i> , who may have an increased susceptibility to thrombotic disorders                                                |
|          | CVD                                  | FXIII V34L RealFast™ Assay    | 7-250 / 7-253    | CE/IVD      | Identifies carriers of the protective 34L variant of Factor XIII (FXIII) among at-risk patients of hereditary thrombophilia                                                                         |
|          | CVD                                  | MTHFR 677C>T RealFast™ Assay  | 7-160 / 7-163    | CE/IVD      | Detects common mutation in the <i>methylenetetrahydrofolate reductase (MTHFR)</i> gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease                              |
|          | CVD                                  | MTHFR 1298A>C RealFast™ Assay | 7-170 / 7-173    | CE/IVD      | Detects common mutation in the <i>methylenetetrahydrofolate reductase (MTHFR)</i> gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease                              |
|          | CVD                                  | PAI-1 4G/5G RealFast™ Assay   | 7-180 / 7-183    | CE/IVD      | Detects the 4G risk allele in the <i>SERPINE1</i> gene, encoding plasminogen activator inhibitor-1 (PAI-1), and is associated with cardiovascular disease and pregnancy complications               |
|          | CVD                                  | PTH 20210G>A RealFast™ Assay  | 7-120 / 7-123    | CE/IVD      | Detects the second most important genetic risk factor for venous thromboembolism in the <i>Factor II</i> gene, encoding prothrombin (PTH)                                                           |
|          | Congenital Adrenal Hyperplasia (CAH) | CAH RealFast™ CNV Assay       | 7-410 / ---      | CE/IVD      | Discriminates between deletions, duplications and normal copy number status of the <i>CYP21A2</i> gene in patients with CAH. Recommended to be used in combination with CAH StripAssay® [REF 4-380] |

# RealFast™ Assays

| Category                                                                          | Clinical Topic         | Product Name                    | REF 100 / 32 Rxn | Reg. Status             | Description                                                                                                                                                                            |
|-----------------------------------------------------------------------------------|------------------------|---------------------------------|------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | Genetic Predisposition | HLA-B27 RealFast™ Assay         | 7-620 / 7-623    | IVDR CE <sub>0123</sub> | Detects the human leukocyte antigen (HLA) <i>HLA-B*27</i> allele, which is associated with ankylosing spondylitis                                                                      |
|  | Haemochromatosis       | HFE C282Y RealFast™ Assay       | 7-130 / 7-133    | CE/IVD                  | Detects the common C282Y variant in the <i>HFE</i> gene causing hereditary haemochromatosis (HH) type 1                                                                                |
|  | Haemochromatosis       | HFE H63D RealFast™ Assay        | 7-140 / 7-143    | CE/IVD                  | Detects the common H63D variant in the <i>HFE</i> gene causing hereditary haemochromatosis (HH) type 1                                                                                 |
|  | Pharmacogenetics       | CYP2D6 RealFast™ CNV Assay      | 7-420 / ---      | CE/IVD                  | Discriminates between deletions, duplications and normal copy number status of the <i>CYP2D6</i> gene. Recommended to be used in combination with PGX-CYP2D6 XL StripAssay®[REF 4-770] |
|  | Pharmacogenetics       | HLA-B5701 RealFast™ Assay       | 7-610 / 7-613    | CE/IVD                  | Detects the human leukocyte antigen (HLA) <i>HLA-B*57:01</i> allele, which is associated with hypersensitivity to the anti-HIV drug abacavir                                           |
|  | Pharmacogenetics       | IL28B RealFast™ Assay           | 7-200 / 7-203    | CE/IVD                  | Detects a dinucleotide frame-shift variant coding for interleukin 28B (IL28B) and helps to predict the therapeutic response in Hepatitis C Virus infected patients                     |
|  | Pharmacogenetics       | SLCO1B1c.521T>C RealFast™ Assay | 7-210 / 7-213    | CE/IVD                  | Detects a variant in human <i>solute carrier organic anion transporter family member 1B1 (SLCO1B1)</i> gene in patients who are at higher risk for developing statin-induced myopathy  |
|  | Pharmacogenetics       | VKORC1 -1639G>A RealFast™ Assay | 7-190 / 7-193    | CE/IVD                  | Detects the most important polymorphism in the <i>Vitamin K Epoxide Reductase Complex 1 (VKORC1)</i> gene associated with interindividual dose requirements for oral anticoagulants    |


## Multiplex testing - save costs and sample material

| Category                                                                            | Clinical Topic       | Product Name                   | REF 100 / 32 Rxn | Reg. Status | Description                                                                                                                                                                                      |
|-------------------------------------------------------------------------------------|----------------------|--------------------------------|------------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | CVD                  | FV-PTH mpx RealFast™ Assay     | 7-115 / 7-118    | CE/IVD      | Simultaneous detection of the most important thrombophilic mutations 1691G>A in the <i>Factor V</i> gene and 20210G>A in the <i>Factor II</i> gene, encoding prothrombin (PTH)                   |
|  | CVD                  | MTHFR mpx RealFast™ Assay      | 7-165 / 7-168    | CE/IVD      | Simultaneous detection of the most common two mutations in the <i>MTHFR</i> gene: 677C>T and 1298A>C                                                                                             |
|  | AAT deficiency/ COPD | AAT mpx RealFast™ Assay        | 7-265 / 7-268    | CE/IVD      | Detects *S and *Z variants of the <i>SERPINA1</i> gene predisposing individuals to chronic obstructive pulmonary disease (COPD) and liver disease due to deficiency of alpha-1 antitrypsin (AAT) |
|  | Haemochromatosis     | HFE mpx RealFast™ Assay        | 7-135 / 7-138    | CE/IVD      | Simultaneous detection of the two most common mutations in the <i>HFE</i> gene: H63D and C282Y                                                                                                   |
|  | Pharmacogenetics     | CYP2C9 mpx RealFast™ Assay     | 7-225 / 7-228    | CE/IVD      | Simultaneous detection of <i>CYP2C9</i> *2(c.430C>T) and <i>CYP2C9</i> *3(c.1075A>C) polymorphisms to determine the drug response of known targets, like S-warfarin or phenytoin                 |
|                                                                                     | Service              | RealFast™ Confirmation Service | CS-045           | ---         | Service to assist in establishing RealFast™ Assays as well as for performance monitoring                                                                                                         |

## COVID-19 AVAILABLE UPON REQUEST

| Category | Clinical Topic         | Product Name               | REF 100 / 500 Rxn | Reg. Status | Description                                                                                                                               |
|----------|------------------------|----------------------------|-------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
|          | Respiratory Infections | SARS-CoV-2 RealFast™ Assay | 8-410 / 8-412     | CE/IVD      | Detects the viral <i>N</i> and <i>RdRP/ORF1ab</i> genes and the human <i>ACTB</i> gene as internal control in a multiplex one-step RT-PCR |

IVDR CE<sub>0123</sub>: Products marked with this symbol comply to the Regulation (EU) 2017/746 on *in vitro diagnostic* devices (IVDR) and have been approved by the Notified Body, TÜV Süd, indicated by CE<sub>0123</sub>.



## StripAssays®


| Category                                                                            | Clinical Topic                       | Product Name                    | REF   | Reg. Status             | Unit Size | Description                                                                                                                            |
|-------------------------------------------------------------------------------------|--------------------------------------|---------------------------------|-------|-------------------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------|
|    | Alzheimer Disease                    | Apo E StripAssay®               | 4-280 | CE/IVD                  | 20 tests  | Detection of isoforms Apo E2, E3 and E4                                                                                                |
|    | Cancer                               | BRAF 600/601 StripAssay®        | 5-560 | CE/IVD                  | 20 tests  | Ultra-sensitive detection of 9 <i>BRAF</i> mutations in codons 600 and 601                                                             |
|    | Cancer                               | EGFR XL StripAssay®             | 5-630 | CE/IVD                  | 20 tests  | Ultra-sensitive detection of 30 <i>EGFR</i> mutations in exons 18/19/20/21                                                             |
|    | Cancer                               | FCGR StripAssay®                | 5-670 | RUO                     | 20 tests  | Detection of allelic variants of Fc gamma-Receptor 2A (H131R) and 3A (F158V) associated with response to IgG antibody therapy          |
|   | Cancer                               | KRAS XL StripAssay®             | 5-680 | CE/IVD                  | 20 tests  | Ultra-sensitive detection of 29 <i>KRAS</i> mutations in codons 12/13/59/60/61/117/146                                                 |
|  | Cancer                               | NRAS XL StripAssay®             | 5-620 | CE/IVD                  | 20 tests  | Ultra-sensitive detection of 22 <i>NRAS</i> mutations in codons 12/13/59/60/61/146                                                     |
|  | Carbohydrate Intolerance             | Lactose Intolerance StripAssay® | 4-300 | CE/IVD                  | 20 tests  | Detection of two <i>lactase</i> gene polymorphisms -13910T>C and -22018A>G                                                             |
|  | Carbohydrate Intolerance             | Sugar Intolerance StripAssay®   | 4-310 | CE/IVD                  | 20 tests  | Detection of two <i>lactase</i> gene polymorphisms and four <i>aldolase B</i> gene mutations                                           |
|  | Cardiovascular Diseases (CVD)        | CVD StripAssay®                 | 4-240 | CE/IVD                  | 20 tests  | Testing for 12 genetic variants associated with cardiovascular diseases                                                                |
|  | CVD                                  | CVD StripAssay® A               | 4-370 | CE/IVD                  | 20 tests  | Testing for 8 genetic variants predisposing to atherosclerosis                                                                         |
|  | CVD                                  | CVD StripAssay® T               | 4-360 | CE/IVD                  | 20 tests  | Testing for 9 genetic variants predisposing to venous thromboembolism                                                                  |
|  | CVD                                  | FV-PTH StripAssay®              | 4-290 | CE/IVD                  | 20 tests  | Detection of the <i>Factor V</i> Leiden and <i>Factor II</i> , encoding prothrombin (PTH), gene mutations                              |
|  | CVD                                  | FV-PTH-MTHFR StripAssay®        | 4-260 | CE/IVD                  | 20 tests  | Detection of the <i>Factor V</i> Leiden, <i>Factor II</i> , encoding prothrombin (PTH), and <i>MTHFR</i> gene mutations                |
|  | Congenital Adrenal Hyperplasia (CAH) | CAH StripAssay®                 | 4-380 | IVDR CE <sub>0123</sub> | 20 tests  | Testing for 11 most prevalent <i>CYP21A2</i> mutations. Recommended to be used in combination with CAH RealFast™ CNV Assay [REF 7-410] |
|  | Cystic Fibrosis (CF)                 | CF StripAssay®                  | 4-410 | IVDR CE <sub>0123</sub> | 10 tests  | Detection of 34 common <i>CFTR</i> mutations and the IVS8 variants 5T/7T/9T                                                            |
|  | CF                                   | CF StripAssay® GER              | 4-430 | IVDR CE <sub>0123</sub> | 10 tests  | Detection of 31 common <i>CFTR</i> mutations                                                                                           |
|  | CF                                   | CF StripAssay® TUR              | 4-420 | IVDR CE <sub>0123</sub> | 10 tests  | Detection of 24 common <i>CFTR</i> mutations and the IVS8 variants 5T/7T/9T                                                            |
|  | CF                                   | CF StripAssay® EXT              | 4-440 | IVDR CE <sub>0123</sub> | 10 tests  | Detection of 38 common <i>CFTR</i> mutations and the IVS8 variants 5T/7T/9T                                                            |
|  | Familial Mediterranean Fever (FMF)   | FMF StripAssay®                 | 4-230 | IVDR CE <sub>0123</sub> | 20 tests  | Detection of 12 <i>MEFV</i> gene mutations                                                                                             |

| Category                                                                            | Clinical Topic         | Product Name                     | REF    | Reg. Status             | Unit Size | Description                                                                                                                                                                  |
|-------------------------------------------------------------------------------------|------------------------|----------------------------------|--------|-------------------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    | FMF                    | FMF-SAA1 StripAssay®             | 4-390  | IVDR CE <sub>0123</sub> | 20 tests  | Detection of 12 <i>MEFV</i> gene mutations and <i>SAA1</i> genotypes 1.1, 1.3 and 1.5                                                                                        |
|    | Genetic Predisposition | HLA-B27 StripAssay®              | 4-320  | CE/IVD                  | 20 tests  | Detection of all disease-relevant <i>HLA-B*27</i> subtypes                                                                                                                   |
|    | Haemochromatosis       | Haemochromatosis StripAssay® A   | 4-220  | CE/IVD                  | 20 tests  | Detection of 18 mutations: twelve <i>HFE</i> mutations, four <i>TFR2</i> mutations and two <i>FPN1</i> mutations                                                             |
|    | Haemochromatosis       | Haemochromatosis StripAssay® B   | 4-210  | CE/IVD                  | 20 tests  | Detection of 3 <i>HFE</i> gene mutations: C282Y, H63D, S65C                                                                                                                  |
|    | Pharmacogenetics       | PGX-5FU XL StripAssay®           | 4-780  | CE/IVD                  | 20 tests  | Detection of <i>DPYD</i> genetic variants HapB3, DPYD*13, DPYD*2A, p.D949V associated with toxicity of 5-fluorouracil therapy                                                |
|    | Pharmacogenetics       | PGX-CYP2C19 StripAssay®          | 4-750  | CE/IVD                  | 20 tests  | Testing for CYP2C19 variants *1, *2, *3, *4, *5, *6, *7, *8 and *17                                                                                                          |
|    | Pharmacogenetics       | PGX-CYP2D6 XL StripAssay®        | 4-770  | CE/IVD                  | 20 tests  | Testing for CYP2D6 variants *1 - *12, *14, *15*, *17, *29, *35, *39, *40, *41, *58, *114. Recommended to be used in combination with CYP2D6 RealFast™ CNV Assay [REF 7-420]. |
|    | Pharmacogenetics       | PGX-HIV StripAssay®              | 4-710  | CE/IVD                  | 20 tests  | Testing for genotypes associated with response to HIV highly active anti-retroviral therapy                                                                                  |
|    | Pharmacogenetics       | PGX-Thrombo StripAssay®          | 4-730  | CE/IVD                  | 20 tests  | Testing for <i>CYP2C9</i> and <i>VKORC1</i> variants associated with anticoagulant dose requirements                                                                         |
|   | Pharmacogenetics       | PGX-TPMT StripAssay®             | 4-740  | CE/IVD                  | 20 tests  | Testing for <i>TPMT</i> variants *1, *2, *3A, *3B and *3C associated with response to thiopurine therapy                                                                     |
|  | Thalassemia            | α-Globin StripAssay®             | 4-160  | IVDR CE <sub>0123</sub> | 10 tests  | Detection of 21 common α-Globin gene mutations                                                                                                                               |
|  | Thalassemia            | β-Globin StripAssay® MED         | 4-130  | CE/IVD                  | 20 tests  | Detection of 22 mutations covering >90% of β-Globin defects found in Mediterranean countries                                                                                 |
|  | Thalassemia            | β-Globin StripAssay® IME         | 4-140  | CE/IVD                  | 20 tests  | Detection of 22 mutations covering >90% of β-Globin defects found in the Middle East and India                                                                               |
|  | Thalassemia            | β-Globin StripAssay® SEA         | 4-150  | CE/IVD                  | 20 tests  | Detection of 22 mutations covering >90% of β-Globin defects found in Southeast Asia                                                                                          |
|  | Thalassemia            | β-Thal Modifier StripAssay®      | 4-170  | CE/IVD                  | 20 tests  | Testing for 5 polymorphisms associated with severity of β-Thalassemia                                                                                                        |
|                                                                                     | Service                | StripAssay® Confirmation Service | CS-042 | ---                     | ---       | Service to assist in establishing StripAssays® as well as for performance monitoring                                                                                         |

Software

| Area         | Product Name          | REF   | Reg. Status | Unit Size | Application                                                                             |
|--------------|-----------------------|-------|-------------|-----------|-----------------------------------------------------------------------------------------|
| StripAssays® | StripAssay® Evaluator | 6-100 | RUO         | ---       | Software for automated scanning of teststrips, interpretation, and archiving of results |

IVDR CE<sub>0123</sub>: Products marked with this symbol comply to the Regulation (EU) 2017/746 on *in vitro diagnostic* devices (IVDR) and have been approved by the Notified Body, TÜV Süd, indicated by CE<sub>0123</sub>.



## NGS Assays

### Amplicon-based Assays

| Category                                                                             | Clinical Topic        | Product Name                            | REF      | Reg. Status | Unit Size | Description                                                                                                                                                                                                                         |
|--------------------------------------------------------------------------------------|-----------------------|-----------------------------------------|----------|-------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WI  | Intestinal Microbiome | 16S Microbiome + ITS NGS Assay [16 rxn] | 9-131-16 | RUO         | 16 Rxn    | Targeted amplification of the bacterial V3-V4 variable regions of the 16S rRNA gene and the fungal ITS2 region. Includes bioinformatic analysis and report generation for species-level classification of the human gut microbiome. |
| WI  | Intestinal Microbiome | 16S Microbiome + ITS NGS Assay [Set A]  | 9-131    | RUO         | 96 Rxn    | Differs from [Set B] and [Set C] in indexing primers only. Multiplexing up to 288 samples.                                                                                                                                          |
| WI  | Intestinal Microbiome | 16S Microbiome + ITS NGS Assay [Set B]  | 9-132    | RUO         | 96 Rxn    | Differs from [Set A] and [Set C] in indexing primers only. Multiplexing up to 288 samples.                                                                                                                                          |
| WI  | Intestinal Microbiome | 16S Microbiome + ITS NGS Assay [Set C]  | 9-133    | RUO         | 96 Rxn    | Differs from [Set A] and [Set B] in indexing primers only. Multiplexing up to 288 samples.                                                                                                                                          |

### Hybridization capture-based Assays

| Category                                                                            | Clinical Topic    | Product Name                              | REF   | Reg. Status | Unit Size | Description                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------|-------------------|-------------------------------------------|-------|-------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | Genetic Disorders | Clinical Exome Sequencing (CES) NGS Assay | 9-241 | RUO         | (4x4) Rxn | All-in-one solution (library preparation, GENOVESA bioinformatic solution, genetic report generation) for detection of SNVs and InDels in 7500+ clinically relevant genes. Covers the whole coding sequence (CDS) of targeted genes.                                                                           |
|  | Cancer            | Hereditary Cancer NGS Assay               | 9-221 | RUO         | 16 Rxn    | All-in-one solution (library preparation, GENOVESA bioinformatic solution, genetic report generation) targeting the whole CDS of 31 genes. Allows detection of SNVs, InDels, and CNVs of the covered genes (e.g. <i>BRCA1</i> , <i>BRCA2</i> , <i>CDH1</i> ,...).                                              |
|  | Cancer            | Somatic Mutations NGS Assay               | 9-231 | RUO         | 16 Rxn    | All-in-one solution (library preparation, GENOVESA bioinformatic solution, genetic report generation) targeting the whole CDS of genes covered. Detects SNVs and InDels in 10 genes (e.g. <i>BRAF</i> , <i>EGFR</i> , <i>KRAS</i> , ...) and fusions in 3 genes (i.e. <i>ALK</i> , <i>RET</i> , <i>ROS1</i> ). |

MANUFACTURER:



**ViennaLab Diagnostics GmbH**  
Gaudenzdorfer Guertel 43-45  
A-1120 Vienna, Austria  
+43 1 812 0156  
info@viennalab.com  
www.viennalab.com

DISTRIBUTOR:

Supplied by:



Tel: +44 (0)1235 431390  
sales@oxfordbiosystems.com  
www.oxfordbiosystems.com

EN ISO 13485  
October 2024